Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.
Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, Suzuki H, Ikeda H, Kijima T, Matsumoto H, Kanazu M, Hino A, Inaba M, Tsukita Y, Arai D, Maruyama H, Hara S, Tsumura S, Kobe H, Sumikawa H, Sakata S, Yamamoto N. Imaji M, et al. Among authors: hino a. Eur J Cancer. 2023 Jan;179:15-24. doi: 10.1016/j.ejca.2022.10.029. Epub 2022 Nov 12. Eur J Cancer. 2023. PMID: 36470023
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: hino a. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Ikeda S, Kato T, Kenmotsu H, Ogura T, Sato Y, Hino A, Harada T, Kubota K, Tokito T, Okamoto I, Furuya N, Yokoyama T, Hosokawa S, Iwasawa T, Kasajima R, Miyagi Y, Misumi T, Okamoto H. Ikeda S, et al. Among authors: hino a. Oncologist. 2022 Sep 2;27(9):720-e702. doi: 10.1093/oncolo/oyac118. Oncologist. 2022. PMID: 35759340 Free PMC article. Clinical Trial.
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Taniguchi Y, Hino A, Hata A, Uchida J, Fukuda Y, Hara S, Kanazu M, Matsumoto H, Kokubo M, Yamamoto N. Sugimoto T, et al. Among authors: hino a. Lung Cancer. 2022 Sep;171:3-8. doi: 10.1016/j.lungcan.2022.07.005. Epub 2022 Jul 13. Lung Cancer. 2022. PMID: 35863254
Effects of participatory organizational interventions on mental health and work performance: A protocol for systematic review and meta-analysis.
Iida M, Sakuraya A, Imamura K, Asaoka H, Arima H, Ando E, Inoue A, Inoue R, Iwanaga M, Eguchi H, Otsuka Y, Kobayashi Y, Komase Y, Kuribayashi K, Sasaki N, Tsuno K, Hino A, Watanabe K, Ebara T, Shimazu A, Kawakami N, Tsutsumi A. Iida M, et al. Among authors: hino a. J Occup Health. 2024 May 28:uiae028. doi: 10.1093/joccuh/uiae028. Online ahead of print. J Occup Health. 2024. PMID: 38805736 Free article.
439 results